Table 3.
BRCA promoter methylation percentages in BRCA1/2-related and sporadic breast carcinomas by methylation-specific multiplex ligation-dependent probe amplification
| Probe | BRCA1C-C, median % (range) | BRCA2-C, median % (range) | Sporadic-C, median % (range) | Test statistica | p Value |
|---|---|---|---|---|---|
| BRCA1.1 | 3 (0–11) | 3 (0–91) | 3 (0–80) | 2494.500 | 0.140 |
| BRCA1.2 | 21 (11–34) | 17 (11–100) | 15 (9–85) | 1795.500 | 0.00006* |
| BRCA1.3 | 11 (5–18) | 9 (5–100) | 7 (3–71) | 1760.600 | 0.00003* |
| BRCA2.1 | 24 (14–56) | 21 (8–100) | 15 (8–43) | 947.500 | 9.85°10−13* |
| BRCA2.2 | 11 (5–27) | 10 (5–100) | 5 (3–15) | 596.000 | 1.00°10−13* |
| BRCA2.3 | 17 (9–33) | 14 (8–100) | 9 (5–18) | 536.500 | 1.00°10−13* |
| BRCA2.4 | 9 (0–18) | 8 (0–100) | 5 (2–12) | 984.500 | 1.95°10−12* |
Abbreviations: BRCA1-C Breast carcinomas from BRCA1 germline mutation carriers, BRCA2-C Breast carcinomas from BRCA2 germline mutation carriers, Sporadic-C Sporadic breast carcinoma
aMann-Whitney U test for BRCA1-C and BRCA2-C together against Sporadic-C
*Statistically significant (two-sided p value <0.05)